Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Venous Thromboembolism 10Neoplasms 8Venous Thrombosis 7Pancreatic Neoplasms 5Thrombosis 4Pulmonary Embolism 4Thromboembolism 3Hemorrhage 3Small Cell Lung Carcinoma 2Sarcoma 2Ovarian Neoplasms 2Lymphoma 2Carcinoma, Non-Small-Cell Lung 2Venous Thormboembolism 1Urinary Bladder Neoplasms 1Thrombocytopenia 1Stroke 1Stomach Neoplasms 1Soft Tissue Neoplasms 1Multiple Myeloma 1Malignant Female Reproductive System Neoplasm 1Lymphoma, Large B-Cell, Diffuse 1Liver Neoplasms 1Leukemia 1Hemostatic Disorders 1Hematoma 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Fibrosis 1

Interventions

Enoxaparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Venous Thormboembolism × Enoxaparin × Clear all
NCT02706249 2021-07-08

Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients

Dana-Farber Cancer Institute

Phase 2 Completed
50 enrolled 7 charts

Venous Thormboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡